In January 2016, the Rongxiang Xu, MD, Center for Regenerative Therapeutics at BIDMC of Harvard Medical School and Rongxiang Xu Center of Regenerative Life Science at USC Davis School of Gerontology were established, which are the research and technological support centers for the global development of regenerative life science and regenerative medical technology. 
In May 2016, The first batch of Chinese regenerative medical experts visited the “Rongxiang Xu, MD, Center for Regenerative Therapeutics” at BIDMC of Harvard Medical School. 
In July 2016, Beijing Rongxiang Regenerative Medicine Research Laboratory became the member of the United Nations Academic Impact (UNAI). 
In November 2016,Rongxiang Xu MD  Professorship in Surgery in the Field of  Regenerative Therapeutics
In May 2015, Kevin Xu assumed the Board Chairman of MEBO International and MEBO International stepped into a new era of international development. 
In September 2015, the Clinton Global Initiative (CGI) Commitment“From Urban to Rural: Training Doctors on Moist Exposed Burn Therapy(MEBT)”was launched, which aimed to train 20,000 doctors in China on the application of regenerative medical technology. 
In 2014, MEBO International held the Decision-making Conference for the Development of the US FDA Clinical Trials in Phoenix, Arizona, America. 
On April 14, 2015, Rongxiang Xu, the inventor of MEBT/MEBO, the founder of regenerative medical technology and HBRRS, the discoverer of human regenerative life, the pioneer of regenerative life economy, the founder of MEBO International, passed away.  

In 2013, given his research on and contributions to the scientific route and methods of regenerating damaged human organs and prolonging human lifespan, Rongxiang Xu was granted the European Informal Forum “Golden Biatec” international prize. 
In 2011, the Demonstration Lecture on the Application of Human Body Regenerative Restoration Science was held, which released the five-year large-sample results of comprehensive application of HBRRS in human body. The restoration of defect organs, the prevention of organ refractory diseases and the regenerative rejuvenation of organs were all realized to a certain extent.
In 2009, Rongxiang Xu published his monograph Human Body Regenerative Restoration Science, marking the birth of human body regenerative restoration science (HBRRS) in China.
In August 2007, Rongxiang Xu released the study report on the tissue organ cloning of 206 tissue organs and cancer cell transformation.
In 2004, the English monograph of Rongxiang Xu Burns Regenerative Medicine and Therapy was published by Karger, a well-known Swiss publishing company.
In 2002, The press conference “Big Bang of Life Science” announcing the achievements of in situ and in vitro regenerative reproduction of human body organs was held, marking the preliminary formation of human body regenerative life science. 
In 2002, the hearing of human body organ regeneration and cloning was held by the Ministry of Science and Technology of the P.R.C.
In 2001, the “roadmap of human tissue organ in situ replication engineering” was declared, which laid the theoretical and clinical application foundation for utilizing the cells in situ and in vivo to treat diseases. 
In 2001, the achievement of in situ and in vitro regeneration and cloning of gastrointestinal organs was released, which is another success in the field of tissue organ regenerative restoration, following the skin in situ regenerative restoration by culturing stem cells in situ.  
In 2000, the scientific platform of “somatic cells transforming into stem cells to regenerative tissues and organs” was submitted for patent application in America.
In 1999, in the research of burned skin regeneration, keratin type-19 expressing stem cells were detected, and the procedures of skin in situ regeneration were decoded. Potential regenerative cell (PRC) as the precursor of keratin type-19 expressing stem cells was discovered and confirmed, its physiological functions were identified, being successfully applied in the in situ regenerative restoration of tissues and organs in clinical practice. 

In 1989, the Chinese Journal of Burns, Wounds & Surface Ulcers started publication.

In 1988, MEBO was approved as a new drug by the Ministry of Health of the P.R.C.
In 1988, MEBT/MEBO was identified as the major scientific and technological achievement of China by the State Scientific and Technological Commission of the P.R.C.
In1987,Beijing Guangming Traditional Chinese Medicine Institute for Burns, Wounds & Ulcers was founded.